TransMedics Group Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2024	2023	2022
Revenue:
Net product revenue	$273,866	$176,069	$79,234
Service revenue	167,674	65,554	14,225
Total revenue	441,540	241,623	93,459
Cost of revenue:
Cost of net product revenue	58,345	41,015	16,970
Cost of service revenue	121,114	46,515	11,217
Total cost of revenue	179,459	87,530	28,187
Gross profit	262,081	154,093	65,272
Operating expenses:
Research, development and clinical trials	55,968	36,055	26,812
Acquired in-process research and development expenses	—	27,212	—
Selling, general and administrative	168,617	119,553	69,897
Total operating expenses	224,585	182,820	96,709
Income (loss) from operations	37,496	(28,727)	(31,437)
Other income (expense):
Interest expense	(14,409)	(10,791)	(3,726)
Interest income and other income (expense), net	12,693	12,847	(1,002)
Total other income (expense), net	(1,716)	2,056	(4,728)
Income (loss) before income taxes	35,780	(26,671)	(36,165)
(Provision) benefit for income taxes	(316)	1,643	(66)
Net income (loss)	$35,464	$(25,028)	$(36,231)
Net income (loss) per share:
Basic	$1.07	$(0.77)	$(1.23)
Diluted	$1.01	$(0.77)	$(1.23)
Weighted average common shares outstanding:
Basic	33,229,953	32,517,372	29,556,633
Diluted	35,216,837	32,517,372	29,556,633

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.